{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002085","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.169047+00:00","generated_at":"2026-06-07T01:53:47.427378+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rigel prelim Q4 2023 total revenue ~$35.7M; TAVALISSE record $25.7M; MD Anderson deal $15M","bullets":["Prelim Q4 total revenue ~$35.7M: TAVALISSE net sales $25.7M (record), REZLIDHIA $3.9M.","Full-year 2023 net product sales $104.3M (+36% YoY); cash & investments $56.9M at year-end.","Strategic collaboration with MD Anderson to advance REZLIDHIA in AML and other cancers; $15M in milestones over 5 years.","Collaboration with CONNECT for Phase 2 trial of REZLIDHIA in IDH1-mutant glioma; Rigel funding up to $3M.","Phase 1b trial of R289 (IRAK1/4 inhibitor) in lower-risk MDS currently enrolling third cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002085","json":"https://secwatch.observer/filing/0001104659-24-002085.json","markdown":"https://secwatch.observer/filing/0001104659-24-002085.md","text":"https://secwatch.observer/filing/0001104659-24-002085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924002085/0001104659-24-002085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924002085/tm242328d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:53:47.427378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"942f53c2db1e11a1c4386bdfbbd7cf8723617c93","claim":"RIGEL PHARMACEUTICALS INC reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $35.7 million.","evidence_excerpt":"--- EX-99.1 2 tm242328d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update · Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million · Strategic alliance with MD Anderson to advance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924002085/0001104659-24-002085-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$35.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}